Express Scripts Rewards Low List-Priced Brands In 2019 Formulary, Retains Focus On Rebates
Executive Summary
Mylan’s Symfi and Merck’s Zepatier gain preferred status on PBM's national preferred formulary for 2019. But more drugs are excluded from coverage – 242, up from 196 in 2018.
You may also be interested in...
Insurer Incentives For Lower-Cost HIV Drugs Not Seen As Significant Threat For Gilead, ViiV
UnitedHealthcare offers HIV-infected patients a financial incentive to switch to lower-cost therapy, including generic TDF, but analysts suspect the savings won’t be enough to encourage much switching away from Gilead’s single-tablet regimens.
Pfizer Launches Nivestym At An Aggressive Discount To Other Filgrastim Products
Pfizer is launching its second US biosimilar, a version of filgrastim, at an aggressive 30.3% discount to Amgen's branded Neupogen and at a discount to competing biosimilars.
Pfizer Launches Nivestym At An Aggressive Discount To Other Filgrastim Products
Pfizer is launching its second US biosimilar, a version of filgrastim, at an aggressive 30.3% discount to Amgen's branded Neupogen and at a discount to competing biosimilars.